Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Carolyn A. Leverett"'
Autor:
Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma L. McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France, Simon Berritt, Simone V. Bigi-Botterill, Tony S. Gibson, Rebecca B. Watson, Yiyang Liu, Christopher J. O’Donnell
Publikováno v:
Journal of medicinal chemistry. 65(14)
New drugs introduced to the market are privileged structures that have affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody-drug conjugates (ADCs)
Autor:
Xidong Feng, Ye Che, Adam M. Gilbert, Reto Horst, Kris A. Borzilleri, Matthew Merrill Hayward, Carolyn A. Leverett, James Schiemer, Yilin Meng, Justin I. Montgomery, Matthew F. Calabrese, Mark C. Noe, Daniel P. Uccello, Stephen P. Brown, Matthew Frank Brown, Yingrong Xu
Publikováno v:
Nature Chemical Biology. 17:152-160
Heterobifunctional chimeric degraders are a class of ligands that recruit target proteins to E3 ubiquitin ligases to drive compound-dependent protein degradation. Advancing from initial chemical tools, protein degraders represent a mechanism of growi
Autor:
Peter Morse, Hong X. Ding, Emma McInturff, Andrew C Flick, Subham Mahapatra, Jacob C. DeForest, Sarah J. Fink, Carolyn A. Leverett, Christopher J Helal, Christopher J. O’Donnell
Publikováno v:
Journal of Medicinal Chemistry. 63:10652-10704
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This
Autor:
Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France, Simon Berritt, Simone V. Bigi-Botterill, Tony S. Gibson, Yiyang Liu, Christopher J. O’Donnell
Publikováno v:
Journal of medicinal chemistry. 64(7)
New drugs introduced to the market are privileged structures having affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody-drug conjugates, provide
Publikováno v:
Journal of Medicinal Chemistry. 61:7004-7031
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities provide insight into molecular recognition while serving as leads for designing future new drugs. This annual
Autor:
Christopher J. O’Donnell, Carolyn A. Leverett, Sarah J. Fink, Kevin K.-C. Liu, Hong X. Ding, Andrew C. Flick, Robert E. Kyne
Publikováno v:
Journal of Medicinal Chemistry. 60:6480-6515
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This
Autor:
Emma McInturff, Sarah J. Fink, Carolyn A. Leverett, Hong X. Ding, Christopher John Helal, Andrew C Flick, Christopher J. O’Donnell
Publikováno v:
Journal of medicinal chemistry. 62(16)
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This
Autor:
Judy Lucas, Guoyun Bai, Christopher J. O’Donnell, Sai Chetan K. Sukuru, Brian Rago, Sarah P. Hudson, Carolyn A. Leverett, Lioudmila Tchistiakova, Edmund I. Graziani, Anokha S. Ratnayake, Sylvia Musto, Jeffrey M. Casavant, Joseph Stock, Frank Loganzo, Christine Hosselet, Sujiet Puthenveetil, Andrew J. Bessire, Fengping Li, Xiaogang Han, Tracey Clark, Venkata Doppalapudi, Kimberly Ann Marquette, Beth C. Vetelino, Chakrapani Subramanyam, L. Nathan Tumey
Publikováno v:
ACS Medicinal Chemistry Letters. 7:977-982
As part of our efforts to develop new classes of tubulin inhibitor payloads for antibody-drug conjugate (ADC) programs, we developed a tubulysin ADC that demonstrated excellent in vitro activity but suffered from rapid metabolism of a critical acetat
Autor:
Kevin K.-C. Liu, Carolyn A. Leverett, Christopher J. O’Donnell, Robert E. Kyne, Sarah J. Fink, Hong X. Ding, Andrew C. Flick
Publikováno v:
Bioorganic & Medicinal Chemistry. 23:1895-1922
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition and also serve as leads for designing future new drugs. Thi
Autor:
Andreas Maderna, Carolyn A. Leverett
Publikováno v:
Molecular Pharmaceutics. 12:1798-1812
Dolastatin 10 is a powerful antineoplastic agent and microtubule inhibitor that was discovered by Pettit et al. and published in 1987. Since then, many research groups have engaged in SAR studies of synthetic analogues, termed "auristatins". It was e